Osteoclast Generation

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 175-192

  Takahashi, Naoyuki ^a   Udagawa, Nobuyuki ^a   Kobayashi, Yasuhiro ^a   Takami, Masamichi ^b   Martin, T John ^c   Suda, Tatsuo ^d  

^a MATSUMOTO DENTAL UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^c St Vincent's Public Hospital   (Australia)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873547531     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00029-X     Document Type: Chapter

References (109)

1. S. Akira and K. Takeda (2004) Toll-like receptor signalling. Nat. Rev. Immunol, 4 499-511.
2. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman and L. Galibert (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 175-179.
3. Y. Azuma, K. Kaji, R. Katogi, S. Takeshita and A. Kudo (2000) Tumor necrosis factor-a induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275 4858-4864.
4. S.K. Begg, J.M. Radley, J.W. Pollard, O.T. Chisholm, E.R. Stanley and I. Bertoncello (1993) Delayed hematopoietic development in osteopetrotic (op/op) mice. J. Exp. Med. 177 237-242.
5. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle and W.S. Simonet (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 1260-1268.
6. T.L. Burgess, Y. Qian, S. Kaufman, B.D. Ring, G. Van, C. Capparelli, M. Kelley, H. Hsu, W.J. Boyle, C.R. Dunstan, S. Hu and D.L. Lacey (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145 527-5238.
7. T.J. Chambers, J.M. Owens, G. Hattersley, P.S. Jat and M.D. Noble (1993) Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. Proc. Natl. Acad. Sci. USA 90 5578-5582.
8. B. Chong, M. Hegde, M. Fawkner, S. Simonet, H. Cassinelli, M. Coker, J. Kanis, J. Seidel, C. Tau, B. Tuysuz, B. Yuksel and D. Love and International Hyperphosphatasia Collaborative Group (2003) Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J. Bone Miner. Res. 18 2095-2104.
9. T. Cundy, J. Davidson, M.D. Rutland, C. Stewart and A.M. DePaoli (2005) Recombinant osteoprotegerin for juvenile Paget's disease. N. Engl. J. Med. 353 918-923.
10. T. Cundy, M. Hegde, D. Naot, B. Chong, A. King, R. Wallace, J. Mulley, D.R. Love, J. Seidel, M. Fawkner, T. Banovic, K.E. Callon, A.B. Grey, I.R. Reid, C.A. Middleton-Hardie and J. Cornish (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11 2119-2127.
11. B.G. Darnay, V. Haridas, J. Ni, P.A. Moore and B.B. Aggarwal (1998) Characterization of the intracellular domain of receptor activator of NF-κB (RANK): Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J. Biol. Chem. 273 20551-20555.
12. W.C. Dougall, M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M.E. Tometsko, C.R. Maliszewski, A. Armstrong, V. Shen, S. Bain, D. Cosman, D. Anderson, P.J. Morrissey, J.J. Peschon and J. Schuh (1999) RANK is essential for osteoclast and lymph node development. Genes Dev. 13 2412-2424.
13. P. Ducy, M. Amling, S. Takeda, M. Priemel, A.F. Schilling, F.T. Beil, J. Shen, C. Vinson, J.M. Rueger and G. Karsenty (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 197-207.
14. F. Elefteriou, J.D. Ahn, S. Takeda, M. Starbuck, X. Yang, X. Liu, H. Kondo, W.G. Richards, T.W. Bannon, M. Noda, K. Clement, C. Vaisse and G. Karsenty (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 514-520.
15. A. Erlebacher and R. Derynck (1996) Increased expression of TGF-ß2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132 195-210.
16. R. Felix, M.G. Cecchini and H. Fleisch (1990) Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 127 2592-2594.
17. R. Felix, W. Hofstetter, A. Wetterwald, M.G. Cecchini and H. Fleisch (1994) Role of colony-stimulating factor-1 in bone metabolism. J. Cell Biochem. 55 340-349.
18. E. Filvaroff, A. Erlebacher, J. Ye, S.E. Gitelman, J. Lotz, M. Heillman and R. Derynck (1999) Inhibition of TGF-β receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126 4267-4279.
19. S.W. Fox, K. Fuller, K.E. Bayley, J.M. Lean and T.J. Chambers (2000) TGF-β1 and IFN-γ direct macrophage activation by TNF-α to osteoclastic or cytocidal phenotype. J. Immunol. 165 4957-4963.
20. K. Fuller, B. Kirstein and T.J. Chambers (2006) Murine osteoclast formation and function: differential regulation by humoral agents. Endocrinology 147 1979-1985.
21. K. Fuller, J.M. Lean, K.E. Bayley, M.R. Wani and T.J. Chambers (2000) A role for TGFβ1 in osteoclast differentiation and survival. J. Cell Sci. 113 2445-2453.
22. K. Fuller, B. Wong, S. Fox, Y. Choi and T.J. Chambers (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188 997-1001.
23. L. Galibert, M.E. Tometsko, D.M. Anderson, D. Cosman and W.C. Dougall (1998) The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-?B, a member of the TNFR superfamily. J. Biol. Chem. 273 34120-34127.
24. M.T. Gillespie (2007) Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Res. Ther. 9 103.
25. D.A. Glass II, P. Bialek, J.D. Ahn, M. Starbuck, M.S. Patel, H. Clevers, M.M. Taketo, F. Long, A.P. McMahon, R.A. Lang and G. Karsenty (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8 751-764.
26. Y. Gong, R.B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A.M. Reginato, H. Wang, T. Cundy, F.H. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. Sabatakos, S. Apte, W.N. Adkins, J. Allgrove, M. Arslan-Kirchner, J.A. Batch, P. Beighton, G.C. Black, R.G. Boles, L.M. Boon, C. Borrone, H.G. Brunner, G.F. Carle, B. Dallapiccola, A. De Paepe, B. Floege, M.L. Halfhide, B. Hall, R.C. Hennekam, T. Hirose, A. Jans, H. Juppner, C.A. Kim, K. Keppler-Noreuil, A. Kohlschuetter, D. LaCombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, R.S. Ramesar, M. Romanengo, H. Somer, E. Steichen-Gersdorf, B. Steinmann, B. Sullivan, A. Superti-Furga, W. Swoboda, M.J. van den Boogaard, W. van Hul, M. Vikkula, M. Votruba, B. Zabel, T. Garcia, R. Baron, B.R. Olsen and M.L. Warman and Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 513-523.
27. A. Hikita, I. Yana, H. Wakeyama, M. Nakamura, Y. Kadono, Y. Oshima, K. Nakamura, M. Seiki and S. Tanaka (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J. Biol. Chem. 281 36846-36855.
28. N.J. Horwood, V. Kartsogiannis, J.M. Quinn, E. Romas, T.J. Martin and M.T. Gillespie (1999) Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265 144-150.
29. H. Hsu, D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, E. Timms, H.L. Tan, G. Elliott, M.J. Kelley, I. Sarosi, L. Wang, X.Z. Xia, R. Elliott, L. Chiu, T. Black, S. Scully, C. Capparelli, S. Morony, G. Shimamoto, M.B. Bass and W.J. Boyle (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96 3540-3545.
30. A.E. Hughes, S.H. Ralston, J. Marken, C. Bell, H. MacPherson, R.G. Wallace, W. van Hul, M.P. Whyte, K. Nakatsuka, L. Hovy and D.M. Anderson (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24 45-48.
31. E. Jimi, S. Akiyama, T. Tsurukai, N. Okahashi, K. Kobayashi, N. Udagawa, T. Nishihara, N. Takahashi and T. Suda (1999) Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163 434-442.
32. E. Jimi, I. Nakamura, H. Amano, Y. Taguchi, T. Tsurukai, M. Tamura, N. Takahashi and T. Suda (1996) Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137 2187-2190.
33. E. Jimi, I. Nakamura, L.T. Duong, T. Ikebe, N. Takahashi, G.A. Rodan and T. Suda (1999) Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247 84-93.
34. T.L. Johnson-Pais, F.R. Singer, H.G. Bone, C.T. McMurray, M.F. Hansen and R.J. Leach (2003) Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. J. Bone Miner. Res. 18 376-380.
35. K. Kanazawa and A. Kudo (2005) TRAF2 is essential for TNFα-induced osteoclastogenesis. J. Bone Miner. Res. 20 840-847.
36. M. Kato, M.S. Patel, R. Levasseur, I. Lobov, B.H. Chang, D.A. Glass 2nd, C. Hartmann, L. Li, T.H. Hwang, C.F. Brayton, R.A. Lang, G. Karsenty and L. Chan (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157 303-314.
37. T. Kikuchi, T. Matsuguchi, N. Tsuboi, A. Mitani, S. Tanaka, M. Matsuoka, G. Yamamoto, T. Hishikawa, T. Noguchi and Y. Yoshikai (2001) Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J. Immunol. 166 3574-3579.
38. N. Kim, Y. Kadono, M. Takami, J. Lee, S.H. Lee, F. Okada, J.H. Kimm, T. Kobayashi, P.R. Odgren, H. Nakano, W.C. Yeh, S.K. Lee, J.A. Lorenzo and Y. Choi (2005) Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202 589-595.
39. N. Kim, M. Takami, J. Rho, R. Josien and Y. Choi (2002) A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195 201-209.
40. H. Kitaura, P. Zhou, H.J. Kim, D.V. Novack, F.P. Ross and S.L. Teitelbaum (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115 3418-3427.
41. K. Kobayashi, N. Takahashi, E. Jimi, N. Udagawa, M. Takami, S. Kotake, N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, H. Yasuda, T. Morinaga, K. Higashio, T.J. Martin and T. Suda (2000) Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191 275-286.
42. Y. Kobayashi, T. Mizoguchi, I. Take, S. Kurihara, N. Udagawa and N. Takahashi (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J. Biol. Chem. 280 11395-11403.
43. H. Kodama, A. Yamasaki, M. Nose, S. Niida, Y. Ohgame, M. Abe, M. Kumegawa and T. Suda (1991) Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J. Exp. Med. 173 269-272.
44. T. Koga, M. Inui, K. Inoue, S. Kim, A. Suematsu, E. Kobayashi, T. Iwata, H. Ohnishi, T. Matozaki, T. Kodama, T. Taniguchi, H. Takayanagi and T. Takai (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428 758-763.
45. Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E.R. Bogoch, G. Van, L.T. Nguyen, P.S. Ohashi, D.L. Lacey, E. Fish, W.J. Boyle and J.M. Penninger (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 304-309.
46. Y.Y. Kong, H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C.R. Dunstan, D.L. Lacey, T.W. Mak, W.J. Boyle and J.M. Penninger (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 315-323.
47. T. Kukita, N. Wada, A. Kukita, T. Kakimoto, F. Sandra, K. Toh, K. Nagata, T. Iijima, M. Horiuchi, H. Matsusaki, K. Hieshima, O. Yoshie and H. Nomiyama (2004) RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200 941-946.
48. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney and W.J. Boyle (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 165-176.
49. J. Lam, S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross and S.L. Teitelbaum (2000) TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 1481-1488.
50. J. Li, I. Sarosi, X.Q. Yan, S. Morony, C. Capparelli, H.L. Tan, S. McCabe, R. Elliott, S. Scully, G. Van, S. Kaufman, S.C. Juan, Y. Sun, J. Tarpley, L. Martin, K. Christensen, J. McCabe, P. Kostenuik, H. Hsu, F. Fletcher, C.R. Dunstan, D.L. Lacey and W.J. Boyle (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97 1566-1571.
51. X. Li, Y. Okada, C.C. Pilbeam, J.A. Lorenzo, C.R. Kennedy, R.M. Breyer and L.G. Raisz (2000) Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141 2054-2061.
52. B.Y. Liu, J. Guo, B. Lanske, P. Divieti, H.M. Kronenberg and F.R. Bringhurst (1998) Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139 1952-1964.
53. M.A. Lomaga, W.C. Yeh, I. Sarosi, G.S. Duncan, C. Furlonger, A. Ho, S. Morony, C. Capparelli, G. Van, S. Kaufman, A. van der Heiden, A. Itie, A. Wakeham, W. Khoo, T. Sasaki, Z. Cao, J.M. Penninger, C.J. Paige, D.L. Lacey, C.R. Dunstan, W.J. Boyle, D.V. Goeddel and T.W. Mak (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13 1015-1024.
54. C. Middleton-Hardie, Q. Zhu, H. Cundy, J.M. Lin, K. Callon, P.C. Tong, J. Xu, A. Grey, J. Cornish and D. Naot (2006) Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J. Bone Miner. Res. 21 438-445.
55. A. Mizuno, N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima, N. Washida, E. Tsuda, T. Morinaga, K. Higashio and H. Ozawa (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247 610-615.
56. C.A. Murphy, C.L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R.A. Kastelein, J.D. Sedgwick and D.J. Cua (2003) Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198 1951-1957.
57. A. Naito, S. Azuma, S. Tanaka, T. Miyazaki, S. Takaki, K. Takatsu, K. Nakao, K. Nakamura, M. Katsuki, T. Yamamoto and J. Inoue (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 4 353-362.
58. S. Nakae, A. Nambu, K. Sudo and Y. Iwakura (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171 6173-6177.
59. N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, H. Yasuda, K. Yano, T. Morinaga and K. Higashio (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253 395-400.
60. Y. Nakamichi, N. Udagawa, Y. Kobayashi, M. Nakamura, Y. Yamamoto, T. Yamashita, T. Mizoguchi, M. Sato, M. Mogi, J.M. Penninger and N. Takahashi (2007) Osteoprotegerin reduces the serum level of receptor activator of NF-?B ligand derived from osteoblasts. J. Immunol. 178 192-200.
61. K. Nakatsuka, Y. Nishizawa and S.H. Ralston (2003) Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J. Bone Miner. Res. 18 1381-1385.
62. S. Niida, M. Kaku, H. Amano, H. Yoshida, H. Kataoka, S. Nishikawa, K. Tanne, N. Maeda and H. Kodama (1999) Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190 293-298.
63. S. Niida, T. Kondo, S. Hiratsuka, S. Hayashi, N. Amizuka, T. Noda, K. Ikeda and M. Shibuya (2005) VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc. Natl. Acad. Sci. USA 102 14016-14021.
64. C.A. O'Brien, I. Gubrij, S.C. Lin, R.L. Saylors and S.C. Manolagas (1999) STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-?B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 274 19301-19308.
65. L. Palenzuela, C. Vives-Bauza, I. Fernandez-Cadenas, A. Meseguer, N. Font, E. Sarret, S. Schwartz and A.L. Andreu (2002) Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. J. Med. Genet. 39 E67.
66. J.M. Quinn, K. Itoh, N. Udagawa, K. Hausler, H. Yasuda, N. Shima, A. Mizuno, K. Higashio, N. Takahashi, T. Suda, T.J. Martin and M.T. Gillespie (2001) Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16 1787-1794.
67. Y. Sakuma, K. Tanaka, M. Suda, A. Yasoda, K. Natsui, I. Tanaka, F. Ushikubi, S. Narumiya, E. Segi, Y. Sugimoto, A. Ichikawa and K. Nakao (2000) Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15 218-227.
68. K. Sato, A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, D.J. Cua and H. Takayanagi (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203 2673-2682.
69. N. Sato, N. Takahashi, K. Suda, M. Nakamura, M. Yamaki, T. Ninomiya, Y. Kobayashi, H. Takada, K. Shibata, M. Yamamoto, K. Takeda, S. Akira, T. Noguchi and N. Udagawa (2004) MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1a. J. Exp. Med. 200 601-611.
70. L.A. Schneeweis, D. Willard and M.E. Milla (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-?B ligand. J. Biol. Chem. 280 41155-41164.
71. R.J. Sells Galvin, C.L. Gatlin, J.W. Horn and T.R. Fuson (1999) TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem. Biophys. Res. Commun. 265 233-239.
72. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Luthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Gerby, R. Lee and W.J. Boyle (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89 309-319.
73. N.A. Sims, B.J. Jenkins, J.M. Quinn, A. Nakamura, M. Glatt, M.T. Gillespie, M. Ernst and T.J. Martin (2004) Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J. Clin. Invest. 113 379-389.
74. C. Sobacchi, A. Frattini, M.M. Guerrini, M. Abinun, A. Pangrazio, L. Susani, R. Bredius, G. Mancini, A. Cant, N. Bishop, P. Grabowski, A. Del Fattore, C. Messina, G. Errigo, F.P. Coxon, D.I. Scott, A. Teti, M.J. Rogers, P. Vezzoni, A. Villa and M.H. Helfrich (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39 960-962.
75. G.J. Spencer, J.C. Utting, S.L. Etheridge, T.R. Arnett and P.G. Genever (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NF-?B ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 119 1283-1296.
76. K. Suda, N. Udagawa, N. Sato, M. Takami, K. Itoh, J.T. Woo, N. Takahashi and K. Nagai (2004) Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172 2504-2510.
77. T. Suda, E. Jimi, I. Nakamura and N. Takahashi (1997) Role of 1 a, 25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol. 282 223-235.
78. T. Suda, I. Nakamura, E. Jimi and N. Takahashi (1997) Regulation of osteoclast function. J. Bone Miner. Res. 12 869-879.
79. T. Suda, N. Takahashi and T.J. Martin (1992) Modulation of osteoclast differentiation. Endocr. Rev. 13 66-80.
80. T. Suzawa, C. Miyaura, M. Inada, T. Maruyama, Y. Sugimoto, F. Ushikubi, A. Ichikawa, S. Narumiya and T. Suda (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. Endocrinology 141 1554-1559.
81. N. Takahashi, T. Akatsu, N. Udagawa, T. Sasaki, A. Yamaguchi, J.M. Moseley, T.J. Martin and T. Suda (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 2600-2602.
82. N. Takahashi, N. Udagawa, T. Akatsu, H. Tanaka, Y. Isogai and T. Suda (1991) Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 128 1792-1796.
83. M. Takami, N. Takahashi, N. Udagawa, C. Miyaura, K. Suda, T.J. Woo, T.J. Martin, K. Nagai and T. Suda (2000) Intracellular calcium and protein kinase C mediate expression of receptor activator of NF-?B ligand and osteoprotegerin in osteoblatsts. Endocrinology 141 4711-4719.
84. M. Takami, J.T. Woo, N. Takahashi, T. Suda and K. Nagai (1997) Ca2+-ATPase inhibitors and Ca2+-ionophore induce osteoclast-like cell formation in the cocultures of mouse bone marrow cells and calvarial cells. Biochem. Biophys. Res. Commun. 237 111-115.
85. H. Takayanagi (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7 292-304.
86. S. Takeda, F. Elefteriou, R. Levasseur, X. Liu, L. Zhao, K.L. Parker, D. Armstrong, P. Ducy and G. Karsenty (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111 305-317.
87. S. Takeda, T. Yoshizawa, Y. Nagai, H. Yamato, S. Fukumoto, K. Sekine, S. Kato, T. Matsumoto and T. Fujita (1999) Stimulation of osteoclast formation by 1, 25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: Studies using VDR knockout mice. Endocrinology 140 1005-1008.
88. T. Tamura, N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, T. Taga, T. Kishimoto and T. Suda (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA 90 11924-11928.
89. S. Tanaka, N. Takahashi, N. Udagawa, T. Tamura, T. Akatsu, E.R. Stanley, T. Kurokawa and T. Suda (1993) Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91 257-263.
90. Y.T. Teng, H. Nguyen, X. Gao, Y.Y. Kong, R.M. Gorczynski, B. Singh, R.P. Ellen and J.M. Penninger (2000) Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106 R59-rR67.
91. The American Society for Bone and Mineral Research President's Committee on Nomenclature (2000) Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 15 2293-2296.
92. K. Thirunavukkarasu, R.R. Miles, D.L. Halladay, X. Yang, R.J. Galvin, S. Chandrasekhar, T.J. Martin and J.E. Onyia (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-β). Mapping of the OPG promoter region that mediates TGF-β effects. J. Biol. Chem. 276 36241-36250.
93. E. Tsuda, M. Goto, S. Mochizuki, K. Yano, F. Kobayashi, T. Morinaga and K. Higashio (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234 137-142.
94. N. Udagawa, N. Takahashi, T. Akatsu, T. Sasaki, A. Yamaguchi, H. Kodama, T.J. Martin and T. Suda (1989) The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125 1805-1813.
95. N. Udagawa, N. Takahashi, T. Katagiri, T. Tamura, S. Wada, D.M. Findlay, T.J. Martin, H. Hirota, T. Taga, T. Kishimoto and T. Suda (1995) Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182 1461-1468.
96. N. Udagawa, N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, T. Shinki, T. Gillespie, T.J. Martin, K. Higashio and T. Suda (2000) Osteoprotegerin (OPG) produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141 3478-3484.
97. M.R. Wani, K. Fuller, N.S. Kim, Y. Choi and T. Chambers (1999) Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140 1927-1935.
98. G. Wesolowski, L.T. Duong, P.T. Lakkakorpi, R.M. Nagy, K. Tezuka, H. Tanaka, G.A. Rodan and S.B. Rodan (1995) Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells. Exp. Cell. Res. 219 679-686.
99. M.P. Whyte and A.E. Hughes (2002) Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone Miner. Res. 17 26-29.
100. M.P. Whyte, S.E. Obrecht, P.M. Finnegan, J.L. Jones, M.N. Podgornik, W.H. McAlister and S. Mumm (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347 175-184.
101. M.P. Whyte, P.N. Singhellakis, M.B. Petersen, M. Davies, W.G. Totty and S. Mumm (2007) Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B “Balkan” mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J. Bone Miner. Res. 22 938-946.
102. B.R. Wong, J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F.S. Bartlett III, W.N. Frankel, S.Y. Lee and Y. Choi (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 25190-25194.
103. M. Yagi, T. Miyamoto, Y. Sawatani, K. Iwamoto, N. Hosogane, N. Fujita, K. Morita, K. Ninomiya, T. Suzuki, K. Miyamoto, Y. Oike, M. Takeya, Y. Toyama and T. Suda (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells..J. Exp. Med. 202 345-351.
104. K. Yamaguchi, M. Kinosaki, M. Goto, F. Kobayashi, E. Tsuda, T. Morinaga and K. Higashio (1998) Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem. 273 5117-5123.
105. T. Yamane, T. Kunisada, H. Tsukamoto, H. Yamazaki, H. Niwa, S. Takada and S.I. Hayashi (2001) Wnt signaling regulates hemopoiesis through stromal cells. J. Immunol. 167 765-772.
106. Y. Yamamoto, N. Udagawa, S. Matsuura, Y. Nakamichi, H. Horiuchi, A. Hosoya, M. Nakamura, H. Ozawa, K. Takaoka, J.M. Penninger, T. Noguchi and N. Takahashi (2006) Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-κB ligand. Endocrinology 147 3366-3374.
107. H. Yasuda, N. Shima, N. Nakagawa, S.I. Mochizuki, K. Yano, N. Fujise, Y. Sato, M. Goto, K. Yamaguchi, M. Kuriyama, T. Kanno, A. Murakami, E. Tsuda, T. Morinaga and K. Higashio (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 1329-1337.
108. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi and T. Suda (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 3597-3602.
109. H. Yoshida, S. Hayashi, T. Kunisada, M. Ogawa, S. Nishikawa, H. Okamura, T. Sudo and L.D. Shultz (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345 442-444.